• NEWS . 14 Dec 2020
  • Elevated serum lipoprotein(a) linked to risk of periprocedural myocardial injury in patients undergoing PCI

  • Studies and guidelines have indicated lipoprotein(a) [Lp(a)] as an independent risk factor of arteriosclerotic cardiovascular disease. Considering this, a study was conducted to examine the relationship between serum Lp(a) levels and the risk of periprocedural myocardial injury after percutaneous coronary intervention (PCI) in coronary heart disease (CHD) patients. Study participants comprised a total of 528 non-acute myocardial infarction CHD patients who successfully underwent PCI. 

    Results showed that after multivariate adjustment, increased Lp(a) levels were significantly and independently associated with the risk of elevated postprocedural cardiac troponin I (cTnI) values above 1× upper limit of normal (ULN), 5× ULN, 10× ULN and 15× ULN. As a categorical variable, Lp(a) >300 mg/L was an independent risk factor of postprocedural TnI ≥1× ULN, ≥5× ULN and ≥10× ULN. 

    The study therefore concluded that elevated preprocedural Lp(a) levels were associated with the risk of PCI-related myocardial injury in non-acute myocardial infarction CHD patients.

    Reference:
    Huang Z, et al. Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention. Clin Cardiol 2020. doi: 10.1002/clc.23520. [Epub ahead of print].